-transparent.png){kind=logo}
Somatostatin has been shown to inhibit intestinal secretion induced by a variety of secretagogues. The ability of somatostatin to reduce stool output in patients with cholera was therefore investigated in a double-blind randomized controlled trial. Twenty-two patients with severe purging due to infection with Vibrio cholerae (less than or equal to 12.5 ml/kg X h) received either somatostatin at a dose of 250 micrograms/h in saline (n = 12) or placebo (n = 10). The study drug was given for 12 h followed by a control period of the same duration. No difference in stool output was apparent between somatostatin- and placebo-treated groups. No side effects of somatostatin were observed. It is concluded that somatostatin is ineffective as an antidiarrheal agent in Asiatic cholera in humans.
A M Molla, and
K Gyr, and
P K Bardhan, and
A Molla
May 1994,
Journal of clinical microbiology,
A M Molla, and
K Gyr, and
P K Bardhan, and
A Molla
September 2008,
Infection and immunity,
A M Molla, and
K Gyr, and
P K Bardhan, and
A Molla
May 1994,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
A M Molla, and
K Gyr, and
P K Bardhan, and
A Molla
September 1990,
The Journal of pediatrics,
A M Molla, and
K Gyr, and
P K Bardhan, and
A Molla
August 1995,
Diagnostic microbiology and infectious disease,
A M Molla, and
K Gyr, and
P K Bardhan, and
A Molla
May 1994,
Lancet (London, England),
A M Molla, and
K Gyr, and
P K Bardhan, and
A Molla
January 1991,
Medicina,
A M Molla, and
K Gyr, and
P K Bardhan, and
A Molla
June 1995,
Surgical endoscopy,
A M Molla, and
K Gyr, and
P K Bardhan, and
A Molla
January 1980,
Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Bacteriologia, virusologia, parazitologia, epidemiologia,
A M Molla, and
K Gyr, and
P K Bardhan, and
A Molla
February 1994,
Releve epidemiologique hebdomadaire,
